Press release content from PR Newswire. The AP news staff was not involved in its creation.
Click to copy
SAN DIEGO, Oct. 10, 2020 /PRNewswire/ — The Forbes School of Business & Technology (FSBT) at Ashford University is pleased to announce that Dr. V. Brooks Dunbar, CEO and founder of the Center for Confidence, has joined the Master of Business Administration (MBA) advisory committee.
Dr. Dunbar is an author, speaker, conversationalist, confidence coach, and executive leadership coach. As well as being the founder, Dr. Dunbar is the lead coach at the Center for Confidence, LLC, which provides executive and leadership coaching and other niche coaching services to individuals and organizations. The Center is also a recertification provider for the Society for Human Resource Management (SHRM).
Among her professional accomplishments, Dr. Dunbar created the Center for Confidence’s Discover Your Confidence Zones, a personal audit system designed to help individuals unleash
American companies promising to hire more Black employees in leadership roles and teach their workforce about racism are getting a message from President Donald Trump’s administration: Watch your step if you want to keep doing business with the federal government.
Trump’s Labor Department is using a 55-year-old presidential order spurred by the Civil Rights Movement to scrutinize companies like Microsoft and Wells Fargo over their public commitments to diversity. Government letters sent last week warned both companies against using “discriminatory practices” to meet their goals.
Microsoft has brushed off the warnings, publicly disclosing the government inquiry and defending its plan to boost Black leadership.
But advocates for corporate diversity initiatives worry that more cautious executives will halt or scale back efforts to make their workplaces more inclusive out of fear that a wrong step could jeopardize lucrative public contracts. The agency has oversight over the hiring practices of thousands of
President Donald Trump has been celebrating the dose of experimental monoclonal antibodies he was given last Friday, saying he thinks it helped him vanquish his coronavirus infection in record time.
“It was incredible the impact it had,” he said in a video he tweeted Thursday.
What he didn’t say is that the treatment was developed using technology his administration has worked for four years to ban.
It has to do with abortion politics, and the science of using human tissue to test and to make medicines. Regeneron’s therapy indirectly relied on tissue taken from an abortion.
Trump’s base, of course, is strongly against abortion rights and his administration acted quickly to reverse many Obama era policies — including policies that moved forward scientific research involving human fetal tissue.
Especially involved are human embryonic stem cells, made using days-old embryos, usually taken from fertility clinics. They’re
Trump administration on Tuesday announced the interim final rule that restricts H-1B visas to protect American workers.
The new rules include tightening the currently regulations proposed by Department of Homeland Security and new wage rules for the skilled immigration visa, proposed by the Department of labor. While the former will come into to effect 60 days after publishing in the Federal Register, the latter will come into effect on Thursday right after publishing.
These regulations are also expected to impact a third of H-1B petitions. Immigration experts pointed out that these changes are expected to be challenged in the court.
The new rule will do three things.
1. It will narrow the definition of specialty occupation.
2. Additional documentation required by companies to prove that they need the H-1B workers to
Washington: The Trump administration has announced new restrictions on H-1B nonimmigrant visa programme which it said is aimed at protecting American workers, restoring integrity and to better guarantee that H-1B petitions are approved only for qualified beneficiaries and petitioners, a move which is likely to affect thousands of Indian IT professionals.
The interim final rule announced by the Department of Homeland Security on Tuesday, less than four weeks ahead of the US presidential election, will narrow the definition of “specialty occupation” as Congress intended by closing the overbroad definition that allowed companies to game the system.
It will also require companies to make “real” offers to “real employees,” by closing loopholes and preventing the displacement of the American workers. And finally, the new rules would enhance the department’s
The agencies have not published a copy of the new regulations, leaving hundreds of thousands of engineers, doctors and other skilled professionals mostly guessing about the scope of their impact, even as Trump administration officials described the measures in superlative terms.
“In DHS’s history, we have never done as much in the H-1B space as we are announcing today,” said Ken Cuccinelli, the senior official performing the duties of the DHS deputy secretary.
Cuccinelli and Patrick Pizzella, the deputy labor secretary, told reporters the measures were being implemented using an expedited process because of the coronavirus pandemic’s impact on the U.S. workforce.
“With millions of Americans looking for work and as the economy continues its recovery, immediate action is needed to guard against the risk that lower-cost foreign labor can pose to the well-being of U.S. workers,” Pizzella told reporters on a conference call.
Australia’s Therapeutic Goods Administration (TGA) is getting a digital makeover, after the federal government announced on Friday it would invest AU$12 million over four years to make it happen.
As part of the revamp, TGA’s business systems and infrastructure will be digitised and cybersecurity measures will be bolstered.
Specifically, it will enable medical companies to use automatic data transfer to deliver drug reaction reports on patient safety from their own internal databases into the TGA Adverse Events Management System (AEMS) database, saving up to 15 minutes per report. This will be a change to the current process that requires reports that are submitted in PDF format, as well as other formats, to be manually entered into the database.
See also: ADHA details My Health Record breach attempt
Minister for Health Greg Hunt touted the revamp would help cut red tape for more than 4,000 businesses that apply to register medicines
A federal study found that oil and gas drilling in Alaska puts polar bears at risk. But U.S. Geological Survey Director James Reilly, the head of the department that conducted the research, refused to make the study public, the Washington Post reported on Wednesday.
The Interior Department’s research looked into the number of polar bears that den and give birth on Alaska’s North Slope near the southern Beaufort Sea. The Trump administration has moved to open up that area to oil and gas drilling and exploration.
Internal memos also obtained by the Post show that the federal research has been complete for at least three months, but Reilly held it up, raising questions about its method of counting polar bear dens and why it uses data collected by a former agency scientist who now works for
FDA’s Office of Pharmaceutical Quality adds new licenses of Simcyp™ Simulator
Certara, a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has again renewed and expanded its licenses of Certara’s biosimulation software, with more than 400 user licenses of Simcyp™ and Phoenix™ platforms. Eleven divisions and offices of the FDA use Certara’s software for internal research and to independently analyze, verify, and review regulatory submissions.
Certara’s Simcyp Simulator, an industry-leading platform for physiologically-based pharmacokinetic (PBPK) modeling and simulation, is used to determine first-in-human dose, design more efficient and effective clinical studies, and predict drug-drug interactions using virtual populations. The FDA’s Office of Clinical Pharmacology has renewed its licenses for the Simcyp Simulator, including Simcyp Pediatric and the Simcyp Cardiac Safety Simulator. Furthermore, the FDA’s Office of Pharmaceutical Quality recently ordered Simcyp user licenses, expanding the FDA’s use of the platform. The agency uses